Morningstar Acciones

AVITA Medical Inc AVH StarRatingValueLabel_4Mr. Lee Davidson, Head of Quantitative Research

Último Precio
2,62
Cambio del día
-0,15|-5,42%

a 26/04/2024
16:10:46 AEST | AUD  Minimum 15 Minutes Delay.

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
2,61 - 2,662,58 - 2,66614.020265.923329,60Mill
Último Cierre52 Week RangeP/BeneficioDividendo %ISIN
2,772,58 - 6,27--AU000000AVH4

Cotización AVITA Medical Inc

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
More...
Cuenta de Resultados
Ingresos29,2334,4250,14
Operating Income-26,54-27,51-42,66
Resultado Neto-26,58-26,67-35,38
Beneficio Básico por Acción-0,23-0,21-0,28
Num Medio Acciones diluidas en circulación113125127
Balance
Activo Corriente121,3387,46104,01
Activos no corrientes4,1710,817,63
Total Activo 125,5098,26111,64
Pasivo corriente7,3910,6913,20
Total Pasivo---
Total Equity115,6684,7449,06
Flujo de Caja
Flujo de caja operativo-25,90-19,09-38,01
Inversiones de Capital-1,17-0,53-1,45
Flujo de Caja Libre-27,08-19,62-39,46

En millones, excepto "EPS básico". Currency is USD.

Perfil de la compañía

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Sector

Atención sanitaria

Industria

Dispositivos Médicos

Estilo de acciones

Peq-Crecim

Fin Ejercicio Fiscal

diciembre

Empleados

207
Datos destacados
More...
Precio/Beneficio 12 m-
Precio/Valor contable4,73
Price/Sales TTM-
Crec Ingresos (media 3 a)43,16
Crec BPA (media 3 a)-
Margen operativo-85,07
Margen neto-70,56
ROE 12 m-52,89
Deuda/Fondos propios0,85
Dividendos
AntLatest
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0,000,00
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. Reservados todos los derechos.

Términos de uso        Política Privacidad        Cookie Settings        Aviso Legal